Nevada Clinical Trials Report — June 2026

For Nevadans considering participation in clinical research, June 2026 presents a critical window of opportunity, with a number of studies nearing their conclusion. Across the state, 29 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 2 trials specifically seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on neurological and dermatological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder (3 trials)
• Atopic dermatitis
• Bipolar disorder I or II with a major depressive episode
• Attention-deficit/hyperactivity disorder
• Behavioral variant frontotemporal dementia (bvFTD)
• Benign prostatic hyperplasia (BPH)
• Atrial fibrillation (AF)
• Bladder pain syndrome
• C9orf72
• Cancer

Significant New Research Initiatives Launch Across Nevada

This month, Nevada welcomes 17 new clinical trials, maintaining the same robust pace as May 2026, which also saw 17 new studies open. These new initiatives include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654361, a Phase 3 "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This substantial global study aims to enroll 3,600 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial from Gasherbrum Bio, Inc. is NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This randomized, double-blind, placebo-controlled study will assess the long-term efficacy, safety, and tolerability of aleniglipron in 1,100 participants living with overweight or obesity and type 2 diabetes.
• For those with type 2 diabetes, AstraZeneca is leading several important Phase 3 studies. NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide," aims for 1,200 participants to evaluate the efficacy and safety of elecoglipron.
• AstraZeneca is also sponsoring NCT07662135, a Phase 3 study to investigate "The Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin," targeting 900 participants.
• Additionally, NCT07662044 from AstraZeneca is a Phase 3 study to investigate "The Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus," planning for 800 participants.
• Individuals experiencing migraines may be interested in two Phase 3 trials sponsored by Kallyope Inc.: NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," targeting 1,800 participants, and NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," aiming for 1,000 participants.
• For bladder cancer detection, Convergent Genomics, Inc. is sponsoring NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer," an observational study planning to enroll 2,500 participants.

Expanding Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are growing opportunities to contribute to medical science. Of the 17 new trials launched this month, 4 are actively seeking healthy volunteers. Statewide, a total of 38 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Conditions addressed by new trials this month that may include healthy volunteers, or are open to a broad range of participants, include creativity and mindfulness, digestive symptoms, and elevated liver enzymes. Remember, 2 of the trials closing within 90 days also accept healthy volunteers, so prompt action is encouraged.

New Research Across Diverse Conditions and Interventions

The 17 new trials opening this month in Nevada cover a diverse range of health conditions, with a strong focus on metabolic health and neurological conditions. The most common conditions addressed by these new studies include:

• Type 2 diabetes mellitus (3 trials)
• Obesity (2 trials)
• Migraine (2 trials)
• Overweight (2 trials)
• Chronic weight management (2 trials)
• Creativity and mindfulness
• Depression
• Digestive symptoms
• Down syndrome (Trisomy 21)
• Elevated liver enzymes

In terms of intervention types, drug trials lead the way, accounting for 10 of the new studies. Device trials and dietary supplement trials each contribute 2 new studies, alongside other types of research including combination products.

Nevada's Research Footprint: Where to Find Trials

Nevada's clinical research landscape continues to be robust, with 533 clinical trials currently recruiting across 13 cities and 392 research sites statewide. This month, the majority of new research initiatives are concentrated in the state's largest metropolitan areas, ensuring accessibility for many residents:

• Las Vegas (15 new trials)
• Reno (4 new trials)
• North Las Vegas (2 new trials)
• Henderson (1 new trial)

This distribution highlights the concentration of research activity in and around the major population centers, providing convenient access for a significant portion of the state's residents.

Broad Eligibility and Leading Sponsors

Clinical trials in Nevada are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 2 include children as participants, and 13 include older adults, ensuring that research benefits diverse age groups. There are also 2 new trials specifically for female participants this month. Industry sponsors continue to drive significant research efforts, with 15 of the new trials sponsored by pharmaceutical companies such as AstraZeneca, Gasherbrum Bio, Inc., and Kallyope Inc., alongside network and other types of sponsors.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Nevada.